iPhones Have A Built-In Motion Sickness Feature That No One Knows About Trump Condemns Recognition of Palestinian Statehood ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta SAN FRANCISCO, August 06, 2025--(BUSINESS WIRE)--Vir Biotechnology, ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

HENDERSON, Nev., May 7, 2025 /PRNewswire/ -- AEROCOR, LLC is proud to announce its official partnership with the Eclipse Jet Owners and Pilots Association (EJOPA) to deliver a Flight Operational ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...